Bioventus Inc. · NASDAQ:BVS
Bioventus — 2025 Piper Sandler Healthcare Conference
9 slides from Bioventus's conference presentation, 2025
Slide 1: Bioventus: Helping Patients Recover and Live Life to the Fullest
Bioventus Helping Patients Recover and Live Life to the Fullest 2025 Piper Sandler Healthcare Conference Rob Claypoole, President and CEO
Slide 2: Forward Looking Statements
Forward Looking Statements Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation t
Slide 3: Bioventus Is A Compelling Investment Opportunity
Bioventus Is A Compelling Investment Opportunity Strong $6.4 Billion Significant Market Leadership Market Opportunity Value Creation * $564M Diversified Portfolio in Large 1 Pain Treatments LTM Global Proforma Revenue & Growing Markets Surgical Hyaluronic Acid Platelet Rich Plasma Solutions Pain Per
Slide 4: Well Positioned to Sustain Improved Execution and Financial Performance
Well Positioned to Sustain Improved Execution and Financial Performance Organic Growth Adjusted EBITDA Margin 14.4% 19.0% 20.2% 17.3% 13.4% 7.0% 3.6% 0.7% 2022 2023 2024 2025 2022 2023 2024 2025 2022 – 2024 growth as shown in year-end earnings release 2025 organic growth reflects mid-point of financ
Slide 5: Driving Above Market Growth Short- and Long-Term By Layering Expansion Opportunities
Driving Above Market Growth Short- and Long-Term By Layering Expansion Opportunities and Emerging Growth Drivers on Top of a Solid Core Market BVS Growth Growth Expectation Emerging DD DD+ PNS &and PNS PRP PRP Expansion MSD DD Ultrasonics & International Ultrasonics and International Core HA, BGS &
Slide 6: Peer Leading Gross Margin Combined with Above Market Growth Provides Consistent Ability to Re-invest
Peer Leading Gross Margin Combined with Above Market Growth Provides Consistent Ability to Re-invest, Accelerate EBITDA Margin, and Increase EPS Peer-leading, consistent mid-70’s gross Funding for Expansion and margin Emerging Growth Opportunities • Enhance market awareness + • Expand sales force •
Slide 7: Accelerating Cash Flow, Enhancing Liquidity and Reducing Net Leverage in 2025 and Beyond
Accelerating Cash Flow, Enhancing Liquidity and Reducing Net Leverage in 2025 and Beyond Creates Future Capital Deployment Optionality Higher EBITDA Free Cash Flow Growth: Nearly 2X 2024 FCF Working Capital Lower Cash Flow Yield*: ~60% Interest Efficiency Expense 2025 Net Leverage*: <2.5x Decrease i
Slide 8: Enhancing Shareholder Value with Strong Execution and Financial Discipline
Enhancing Shareholder Value with Strong Execution and Financial Discipline • Improving Strategic Focus and Execution • Accelerating Growth with a Diversified Portfolio of Short and Long-Term Drivers • Flexibility to Invest While Continuing to Drive Operating Margin Improvement • Sustaining Robust Ca
Slide 9: Thank You
a Thank You @ bioventus’